A Retrospective, Multicenter Study of the Tolerance of Induction Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Radiotherapy With Concomitant Cetuximab in 46 Cases of Squamous Cell Carcinoma of the Head and Neck

Buiret, Guillaume; Combe, C.; Favrel, V.; Pommier, P.; Martin, Laurent; Écochard, René; Fayette, Jérôme; Tartas, Sophie; Ramade, Antoine; Céruse, Philippe

doi:10.1016/j.ijrobp.2009.04.066

Cited by 18 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panel members agreed that many different alternatives are reasonable (including concurrent low-dose weekly cisplatin, weekly taxanes, cetuximab, or combinations thereof), but are inadequately studied, to be specifically recommended. 168 After induction chemotherapy, the use of cetuximab is supported by data from the TREMPLIN study, in which patients with advanced laryngeal or hypopharyngeal cancer who had a major response to induction TPF were randomized to high-dose cisplatin for 3 cycles versus weekly cetuximab concurrent with radiotherapy. Patients on the cetuximab arm tolerated therapy better, had better compliance with drug delivery, and had similar 3-month laryngeal preservation rates to those observed in patients on the cisplatin arm.…”

Section: The Induction Chemotherapy Controversymentioning

confidence: 99%

Head and Neck Cancers

Pfister¹,

Ang²,

Brizel³

et al. 2011

J Natl Compr Canc Netw

212

117

View full text Add to dashboard Cite

Section: The Induction Chemotherapy Controversymentioning

confidence: 99%

Head and Neck Cancers

Pfister¹,

Ang²,

Brizel³

et al. 2011

J Natl Compr Canc Netw

212

117

View full text Add to dashboard Cite

“…First, there has been interest in exploring the use of concurrent cetuximab and radiotherapy following induction chemotherapy (22). This approach may be less toxic and thus better tolerated than one with concurrent chemoradiation; however, to our knowledge there has not been a clinical trial to address this issue.…”

Section: Discussionmentioning

confidence: 99%

Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation

Genden

Misiukiewicz

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. The use of induction chemotherapy prior to chemoradiation for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains controversial. We explored whether toxicity from induction chemotherapy influenced the delivery of concurrent chemoradiation. Among 171 consecutive previously unirradiated patients with HNSCC treated with combined chemotherapy and radiation, we identified 66 patients with stage III-IVB head and neck carcinoma who were treated with induction chemotherapy prior to planned chemoradiation. The most common induction regimen was docetaxel, cisplatin and 5-FU (TPF; 80%) for 2 to 3 cycles. Mean radiation dose was 72 Gy (range, 36-75 Gy). Concurrent chemotherapy regimens included cisplatin (26%), cetuximab (5%) and 5-fluorouracil/hydroxyurea (65%)-based regimens. At a median follow-up of 27 months (range, 9-56 months), the 2-year locoregional control and distant control rates were 85 and 86%, respectively. The 2-year disease-free survival and overall survival rates were 74 and 80%, respectively. Although there were no grade 5 toxicities during induction chemotherapy, 26% of patients required hospitalization for adverse events, including 5% needing intensive care. The most common high grade adverse events were grade 4 neutropenia (21%) and neutropenic fever (17%). Six percent of patients were unable to tolerate concurrent chemotherapy. The 2-year disease-free survival was significantly higher in patients able to complete induction and concurrent chemoradiation as planned (83 vs. 27%, p<0.001). Induction chemotherapy followed by concurrent chemoradiation results in promising survival rates in our cohort of advanced head and neck carcinoma patients. Due to severe toxicities in a subset of patients, this strategy is only recommended in selected high-risk patients who are carefully followed by an experienced multidisciplinary team.

show abstract

“…2,65,66 Recommended agents for CRT after induction include weekly carboplatin or cetuximab. 63,67,68 1.4 | What are the considerations for patients who have distant metastatic disease at initial presentation?…”

Section: What Are the Guidelines For Treatment Of High-risk Resectamentioning

confidence: 99%

“…Due to high toxicity, it is not recommended to follow cisplatin‐based induction with cisplatin‐based CRT . Recommended agents for CRT after induction include weekly carboplatin or cetuximab …”

Section: Introductionmentioning

confidence: 99%

AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma

Fulcher

Haigentz

2017

Head & Neck

View full text Add to dashboard Cite

This article is a continuation of the "Do You Know Your Guidelines" series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)-negative oropharyngeal cancer where applicable, as HPV-positive oropharyngeal squamous cell carcinoma carries a different natural history, different prognosis, and now different staging criteria. Additionally, the article will not include information on nasopharyngeal or sinus cancers, as these latter topics are covered in separate "Do you know your guidelines?" installments and these diagnoses carry somewhat different approaches to diagnosis and management that diverge from the focus of this article.

show abstract

A Retrospective, Multicenter Study of the Tolerance of Induction Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Radiotherapy With Concomitant Cetuximab in 46 Cases of Squamous Cell Carcinoma of the Head and Neck

Cited by 18 publications

References 30 publications

Head and Neck Cancers

Head and Neck Cancers

Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation

AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma

Contact Info

Product

Resources

About